| Literature DB >> 30235836 |
Hongxing Zheng1, Shanshan Qi2, Chen Chen3.
Abstract
Postmenopau<span class="Chemical">sal <span class="Disease">diabetic women have a high risk of fractures. Salidroside has preventive effects on estrogen deficiency-induced osteoporosis and has hypoglycemic effects on diabetes in rats. However, whether salidroside inhibits bone loss in postmenopausal diabetic patients is still unknown. Here, we established a rat model of osteoporosis to investigate the protective effects of salidroside on bone loss induced by ovariectomy combined with diabetes, also investigating the underlying mechanisms. Two-month-old female Sprague-Dawley rats were divided into three equal groups (10 rats in each group): control group (with sham operation, treated with drug vehicle); OVX/T1DM group (ovariectomized diabetic rats); OVX/T1DM-SAL group, comprising ovariectomized diabetic rats treated with salidroside (20 mg/kg body weight) by gavage. The results showed that after 60 consecutive days of treatment, the bone mineral density (BMD) of OVX/T1DM-SAL increased significantly compared with the OVX/T1DM group (p < 0.01). The level of serum bone turnover markers, including alkaline phosphatase (ALP), cross linked c-telopeptide of type I collagen (CTX-1), osteocalcin, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase 5b (TRACP 5b) were all increased in the OVX/T1DM group compared with the control (p < 0.01), and those were decreased by salidroside treatment. Meanwhile, the bone histopathological changes were also attenuated, and the bone marrow adipogenesis was inhibited in salidroside treated rats. Moreover, protein and mRNA ratio of bone osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL) was upregulated in ovariectomized diabetic rats by salidroside treatment. The results above indicated that the protective effect of salidroside on bone loss induced by ovariectomy and diabetes was mainly due to its ability to suppress bone turnover, inhibit bone marrow adipogenesis, and up-regulate the OPG/RANKL ratio.Entities:
Keywords: OPG; RANKL; bone; bone turnover markers; diabetes; osteoporosis; salidroside
Mesh:
Substances:
Year: 2018 PMID: 30235836 PMCID: PMC6225177 DOI: 10.3390/molecules23092398
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structure of salidroside.
Figure 2Effects of salidroside (SAL) on (A) body weight and (B) bone mineral density (BMD) in each experimental group. CON: control group (n = 10); OVX/T1DM: group of ovariectomized diabetic rats (n = 10); OVX/T1DM-SAL: group of ovariectomized diabetic rats administered with SAL (20 mg/kg/day) (n = 10). Values are presented as means ± SD. Different letters indicate statistically significant difference in (A) (a, b, c) and (B) (a, b; each tissue) (p < 0.05, one-way ANOVA followed by Bonferroni post hoc test).
Serum glucose and serum bone turnover markers in each experimental group.
| Parameter | Control | OVX/T1DM | OVX/T1DM-SAL |
|---|---|---|---|
| Glucose (mg/dL) | 90.46 ± 8.14 a | 444.92 ± 29.16 b | 102.39 ± 11.82 a |
| ALP (U/dL) | 102.23 ± 9.71 a | 189.56 ± 17.33 b | 121.67 ± 12.13 a |
| Ca (mg/dL) | 9.41 ± 0.98 a | 4.78 ± 0.57 b | 8.87 ± 0.91 a |
| P (mg/dL) | 6.54 ± 0.79 a | 3.76 ± 0.43 b | 5.01 ± 0.91 c |
| CTX-1 (ng/mL) | 21.43 ± 3.78 a | 104.32 ± 13.45 b | 30.78 ± 4.91 a |
| Osteocalcin (ng/mL) | 19.56 ± 3.59 a | 37.42 ± 4.89 b | 27.31 ± 3.18 c |
| TRACP 5b (U/L) | 1.74 ± 0.20 a | 3.02 ± 0.67 b | 1.97 ± 0.43 a |
| PINP (μg/L) | 40.35 ± 7.56 a | 51.21 ± 8.54 b | 42.67 ± 6.89 a |
| OPG (ng/mL) | 6.78 ± 1.90 a | 2.45 ± 0.56 b | 5.74 ± 0.69 a |
| RANKL (ng/mL) | 1.89 ± 0.56 a | 4.17 ± 0.98 b | 1.99 ± 0.51 a |
| OPG/RANKL ratio | 4.21 ± 0.54 a | 0.62 ± 0.11 b | 3.78 ± 0.37 a |
ALP: alkaline phosphatase; Ca: calcium; P: phosphorus; CTX-1: c-terminal telopeptide of type 1 collagen; TRACP 5b: tartrate-resistant acid phosphatase 5b; PINP: N-terminal propeptide of type I procollagen; OPG: osteoprotegerin; RANKL: receptor activator of nuclear factor-κB ligand; CON: control group (n = 10); OVX/T1DM: group of ovariectomized diabetic rats (n = 10). Values are presented as mean ± standard deviation. Different letters within rows indicate statistically significant difference (p < 0.05, one-way ANOVA followed by Bonferroni post hoc test).
Figure 3The femoral morphology of rats in each group. (A) The femur metaphysis in a rat of control group; (B) The femur metaphysis in a rat of OVX/T1DM group; (C) The femur metaphysis in a rat of the OVX/T1DM-SAL group. Hematoxylin and eosin staining, magnification: 200×. There was a significant difference in cortical thickness (CT) between control and OVX/T1DM group (p < 0.01).
Figure 4Bone histomorphometric parameters in all experimental groups. (A) Bone volume per tissue volume (BV/TV, %); (B) Trabecular thickness (Tb.Th, μm); (C) Trabecular separation (Tb.Sp, μm); (D) Cortical thickness (CT, μm). CON: control group (n = 10); OVX/T1DM: group of ovariectomized diabetic rats (n = 10); OVX/T1DM-SAL: group of ovariectomized diabetic rats administered salidroside (SAL: 20 mg/kg/day) (n = 10). Values are presented as means ± SD. Different letters indicate statistically significant difference (p < 0.05, one-way ANOVA followed by Bonferroni post hoc test).
Figure 5Bone marrow adipocyte parameters in all experimental groups. (A) Femur bone marrow in a rat of control group; (B) Femur bone marrow in a rat of OVX/T1DM group; (C) Femur bone marrow in a rat of OVX/T1DM-SAL group. Hematoxylin and eosin staining, magnification: 400×. (D) Adipocyte density of femur bone marrow in each group (n = 10 in each group); (E) Mean adipocyte diameter of femur bone marrow in each group. Values are presented as means ± SD. Different letters indicate statistically significant difference (p < 0.05, one-way ANOVA followed by Bonferroni post hoc test). Red arrows point to adipocytes.
Figure 6The expression of OPG and RANKL mRNA in bone tissues, and OPG/RANKL mRNA ratio in bone tissues of all experimental groups. CON: control group (n = 10); OVX/T1DM: group of ovariectomized diabetic rats (n = 10); OVX/T1DM-SAL: group of ovariectomized diabetic rats administered salidroside (SAL: 20 mg/kg/day) (n = 10). Values are presented as means ± SD. Different letters (a, b) indicate statistically significant difference in each gene expression group (p < 0.05, one-way ANOVA followed by Bonferroni post hoc test).
Figure 7The expression of OPG and RANKL protein in the femoral bone tissues of each group. CON: control group (n = 10); OVX/T1DM: group of ovariectomized diabetic rats (n = 10); OVX/T1DM-SAL: group of ovariectomized diabetic rats administered with salidroside (SAL: 20 mg/kg/day) (n = 10). Negative control of immunostaining: immunostaining was performed using rabbit IgG in place of the primary antibody. In the immunohistochemical staining, the cells with positive expression of OPG and RANKL are shown in brown. Magnification: 200×.
Figure 8Percentage (%) of the positive staining area of OPG and RANKL in the femoral bone tissues of each group. CON: control group (n = 10); OVX/T1DM: group of ovariectomized diabetic rats (n = 10); OVX/T1DM-SAL: group of ovariectomized diabetic rats administered with salidroside (SAL: 20 mg/kg/day) (n = 10). Values are presented as means ± SD. Different letters (a, b) indicate statistically significant difference in each protein expression group (p < 0.05, one-way ANOVA followed by Bonferroni post hoc test).